$ONCT
Oncternal Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021054536 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q3
Revenue $2.128M $883.0K $590.0K
YoY Change 260.68% 41.73% 8.46%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.802M $3.381M $1.930M
YoY Change 45.18% 44.49% -19.25%
% of Gross Profit
Research & Development $8.963M $0.00 $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.77M $0.00 $4.980M
YoY Change 136.24% -100.0% -9.34%
Operating Profit -$9.637M -$7.690M -$4.395M
YoY Change 119.27% 38.93% -11.19%
Interest Expense $7.000K $8.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$9.630M -$7.682M -$4.400M
YoY Change 118.86% 38.66% -10.02%
Income Tax
% Of Pretax Income
Net Earnings -$9.630M -$7.682M -$4.395M
YoY Change 119.11% 38.79% -10.16%
Net Earnings / Revenue -452.54% -869.99% -744.92%
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$195.0K -$155.6K -$218.6K
COMMON SHARES
Basic Shares Outstanding 49.39M
Diluted Shares Outstanding 49.39M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.38M $103.7M $21.30M
YoY Change 357.18% 524.48% -7.79%
Cash & Equivalents $97.40M $103.7M $21.30M
Short-Term Investments
Other Short-Term Assets $2.140M $3.936M $1.400M
YoY Change 52.86% 181.14% 40.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $99.52M $107.6M $22.70M
YoY Change 338.41% 497.77% -5.81%
LONG-TERM ASSETS
Property, Plant & Equipment $119.0K $162.0K $100.0K
YoY Change 19.0% 62.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $657.0K $658.0K $800.0K
YoY Change -17.88% -17.75% 4.17%
Total Long-Term Assets $776.0K $820.0K $900.0K
YoY Change -13.78% -8.89% -5.16%
TOTAL ASSETS
Total Short-Term Assets $99.52M $107.6M $22.70M
Total Long-Term Assets $776.0K $820.0K $900.0K
Total Assets $100.3M $108.4M $23.60M
YoY Change 324.98% 473.65% -5.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.746M $1.009M $1.000M
YoY Change 174.6% -32.73% -18.77%
Accrued Expenses $2.797M $2.493M $3.273M
YoY Change -14.54% -30.88% 34.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.820M $5.900M $7.600M
YoY Change -23.42% -34.44% 12.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $300.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $300.0K
YoY Change -100.0% -100.0% 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.820M $5.900M $7.600M
Total Long-Term Liabilities $0.00 $0.00 $300.0K
Total Liabilities $5.820M $5.900M $7.900M
YoY Change -26.33% -36.56% 14.49%
SHAREHOLDERS EQUITY
Retained Earnings -$106.1M -$96.40M -$80.20M
YoY Change 32.29% 27.18% 30.58%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $94.48M $102.5M $15.70M
YoY Change
Total Liabilities & Shareholders Equity $100.3M $108.4M $23.60M
YoY Change 324.98% 473.65% -5.78%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q3
OPERATING ACTIVITIES
Net Income -$9.630M -$7.682M -$4.395M
YoY Change 119.11% 38.79% -10.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.380M -$7.603M -$5.320M
YoY Change 19.92% 80.17% 38.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 97.00K 59.00K 9.970M
YoY Change -99.03% -98.78% 49750.0%
NET CHANGE
Cash From Operating Activities -6.380M -7.603M -5.320M
Cash From Investing Activities 0.000
Cash From Financing Activities 97.00K 59.00K 9.970M
Net Change In Cash -6.283M -7.544M 4.650M
YoY Change -235.12% -1357.33% -185.95%
FREE CASH FLOW
Cash From Operating Activities -$6.380M -$7.603M -$5.320M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P4Y4M24D
onct Warrant Weighted Average Remaining Contractual Term Exercised
WarrantWeightedAverageRemainingContractualTermExercised
P4Y6M25D
onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P3Y6M25D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-125000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-111000
onct Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
729000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
102519000
CY2021Q3 onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
97000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1149000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
415000
CY2021Q3 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
2000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1488000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9630000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
94476000
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1165000
CY2020Q3 onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
10087000
CY2020Q3 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
407000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4395000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
15700000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
112951000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
414000
onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
202000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
7000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4162000
us-gaap Net Income Loss
NetIncomeLoss
-23260000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
94476000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1767000
onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
14479000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
9000
us-gaap Net Income Loss
NetIncomeLoss
-14668000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
15700000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2797000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97400000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.12%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company’s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3042000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1446000
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
5000
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
23000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
9000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
27000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10258000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5882000
CY2021Q3 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
310000
CY2020Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
412000
CY2021Q3 onct Accrued Clinical Trials
AccruedClinicalTrials
844000
CY2020Q4 onct Accrued Clinical Trials
AccruedClinicalTrials
980000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1528000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
45000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
45000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
77000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
122000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1800000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1400000
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5031841000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.25
onct Exercise Of Warrants
ExerciseOfWarrants
796931000
onct Warrant Exercised Price Per Share
WarrantExercisedPricePerShare
2.56
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4234910000
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.50
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6019412000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.37
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1732115000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6019412000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.37
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1732115000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1300174000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.79
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1365004000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2107625000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4396700000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
378750000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.66
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
106163000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.89
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6019412000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.37
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.003
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1488000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
17700000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2021Q3 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
4235000
CY2021Q3 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
6019000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11776000

Files In Submission

Name View Source Status
0001564590-21-054536-index-headers.html Edgar Link pending
0001564590-21-054536-index.html Edgar Link pending
0001564590-21-054536.txt Edgar Link pending
0001564590-21-054536-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
onct-10q_20210930.htm Edgar Link pending
onct-10q_20210930_htm.xml Edgar Link completed
onct-20210930.xsd Edgar Link pending
onct-20210930_cal.xml Edgar Link unprocessable
onct-20210930_def.xml Edgar Link unprocessable
onct-20210930_lab.xml Edgar Link unprocessable
onct-20210930_pre.xml Edgar Link unprocessable
onct-ex101_100.htm Edgar Link pending
onct-ex311_7.htm Edgar Link pending
onct-ex312_12.htm Edgar Link pending
onct-ex321_6.htm Edgar Link pending
onct-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending